Pfizer (NYSE:PFE) Stock Price Down 0.8%

Pfizer Inc. (NYSE:PFE) fell 0.8% during trading on Wednesday . The stock traded as low as $27.71 and last traded at $27.78. 3,784,137 shares traded hands during mid-day trading, a decline of 91% from the average session volume of 40,850,707 shares. The stock had previously closed at $27.99.

Wall Street Analyst Weigh In

Several research firms recently weighed in on PFE. Argus lowered Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Morgan Stanley upped their price target on Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a research report on Thursday, May 2nd. BMO Capital Markets restated an “outperform” rating and set a $36.00 target price (up previously from $33.00) on shares of Pfizer in a report on Thursday, May 2nd. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $45.00 target price on shares of Pfizer in a report on Wednesday. Ten analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, Pfizer currently has a consensus rating of “Hold” and an average target price of $35.86.

Pfizer Trading Down 2.1 %

The company has a quick ratio of 0.78, a current ratio of 1.05 and a debt-to-equity ratio of 0.66. The stock has a market capitalization of $155.26 billion, a P/E ratio of -463.42, a P/E/G ratio of 1.10 and a beta of 0.70. The firm’s 50 day simple moving average is $27.77 and its two-hundred day simple moving average is $27.69.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 EPS for the quarter, topping analysts’ consensus estimates of $0.56 by $0.26. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. The business had revenue of $14.88 billion for the quarter, compared to analyst estimates of $13.87 billion. During the same period last year, the company posted $1.23 earnings per share. Pfizer’s quarterly revenue was down 19.5% compared to the same quarter last year. As a group, analysts forecast that Pfizer Inc. will post 2.38 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, June 14th. Investors of record on Friday, May 10th were paid a dividend of $0.42 per share. The ex-dividend date was Thursday, May 9th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.13%. Pfizer’s payout ratio is -2,799.53%.

Institutional Trading of Pfizer

Large investors have recently modified their holdings of the business. Ironvine Capital Partners LLC increased its position in shares of Pfizer by 2.1% during the first quarter. Ironvine Capital Partners LLC now owns 16,953 shares of the biopharmaceutical company’s stock valued at $470,000 after buying an additional 353 shares during the period. Advisor OS LLC grew its stake in shares of Pfizer by 1.0% during the 4th quarter. Advisor OS LLC now owns 35,202 shares of the biopharmaceutical company’s stock valued at $1,013,000 after acquiring an additional 365 shares during the period. Safeguard Investment Advisory Group LLC grew its stake in shares of Pfizer by 3.9% during the 4th quarter. Safeguard Investment Advisory Group LLC now owns 9,987 shares of the biopharmaceutical company’s stock valued at $288,000 after acquiring an additional 371 shares during the period. Lantz Financial LLC boosted its stake in Pfizer by 1.3% in the 1st quarter. Lantz Financial LLC now owns 30,582 shares of the biopharmaceutical company’s stock worth $849,000 after purchasing an additional 381 shares during the period. Finally, Wellington Shields Capital Management LLC raised its holdings in shares of Pfizer by 1.3% during the 1st quarter. Wellington Shields Capital Management LLC now owns 30,750 shares of the biopharmaceutical company’s stock worth $853,000 after acquiring an additional 385 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.